Brookings Report Examines Revenue Streams, Profitability Of HIV Treatments
Brookings Institution’s “TechTank”: How profitable are HIV drugs?
Jake Schneider, research assistant, and Darrell West, vice president and director of governance studies and founding director of the Center for Technology Innovation, both at the Brookings Institution, discuss findings from their newly released report examining the estimated potential returns to private investors in antiretroviral therapies and the profitability of HIV drugs in various countries and regions. The authors offer several recommendations for how to overcome barriers to investment in emerging markets (4/16).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.